| Identification | Back Directory | [Name]
2-(2-((7-(2-(aminomethyl)-3-fluoropyridin-4-yl)benzofuran-5-yl)methoxy)phenyl)acetic acid | [CAS]
2378380-49-3 | [Synonyms]
pelecopan
Pelecopan (Synonyms: BCX9930)
2-(2-((7-(2-(aminomethyl)-3-fluoropyridin-4-yl)benzofuran-5-yl)methoxy)phenyl)acetic acid
Benzeneacetic acid, 2-[[7-[2-(aminomethyl)-3-fluoro-4-pyridinyl]-5-benzofuranyl]methoxy]- | [Molecular Formula]
C23H19FN2O4 | [MOL File]
2378380-49-3.mol | [Molecular Weight]
406.41 |
| Chemical Properties | Back Directory | [Boiling point ]
575.0±45.0 °C(Predicted) | [density ]
1.349±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
4.13±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Pelecopan (BCX9930) is a potent, selective, orally active inhibitor of complement factor D with an IC50 value of 14.3 nM. Pelecopan can target factor D to prevent both intravascular and extravascular hemolysis in PNH. Pelecopan also be used for other alternative pathway (AP) mediated diseases[1][2][3]. | [References]
[1] International Nonproprietary Names for Pharmaceutical Substances (INN)
[2] AustinKulasekararajMD MRCP, FRCPath, et al. BCX9930, a Potent, Selective, Oral Factor D Inhibitor, Demonstrates Proof-of-Concept As Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood (2020) Volume 136, Supplement 1, 5 November 2
[3] XilinChenMDPhD, et al. Preclinical Characterization of BCX9930, a Potent Oral Complement Factor D Inhibitor, Targeting Alternative Pathway-Mediated Diseases Including Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood (2020) Volume 136, Supplement 1, 5 Nove |
|
|